Protara Therapeutics (TARA) Expected to Release Earnings on Monday

Posted by Geri Gentry on Aug 3rd, 2026

Protara Therapeutics (NASDAQ:TARA – Get Free Report) is expected to post its Q2 2026 results before the market opens on Monday, August 10th. Analysts expect the company to announce earnings of ($0.3257) per share for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 13, 2026 at 9:30 AM ET.

Protara Therapeutics (NASDAQ:TARA – Get Free Report) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.05. On average, analysts expect Protara Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Protara Therapeutics Trading Up 0.4%

TARA stock traded up $0.01 during mid-day trading on Monday, hitting $3.94. 39,620 shares of the company were exchanged, compared to its average volume of 856,555. The company has a market capitalization of $221.16 million, a PE ratio of -2.92 and a beta of 1.48. Protara Therapeutics has a twelve month low of $2.97 and a twelve month high of $7.82. The firm has a fifty day simple moving average of $4.13 and a 200 day simple moving average of $5.11.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on TARA shares. Oppenheimer boosted their price target on Protara Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a report on Wednesday, May 20th. JPMorgan Chase & Co. dropped their price target on shares of Protara Therapeutics from $27.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, May 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Protara Therapeutics in a research note on Friday, July 17th. HC Wainwright restated a “buy” rating on shares of Protara Therapeutics in a report on Wednesday, May 20th. Finally, UBS Group reiterated a “buy” rating on shares of Protara Therapeutics in a research report on Wednesday, May 20th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $26.25.

View Our Latest Research Report on TARA

Institutional Investors Weigh In On Protara Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of TARA. Virtu Financial LLC bought a new stake in Protara Therapeutics in the 4th quarter valued at $368,000. ADAR1 Capital Management LLC grew its position in Protara Therapeutics by 3,127.4% during the fourth quarter. ADAR1 Capital Management LLC now owns 1,136,799 shares of the company’s stock worth $6,059,000 after buying an additional 1,101,576 shares in the last quarter. XTX Topco Ltd bought a new position in Protara Therapeutics during the fourth quarter valued at about $615,000. Sphera Funds Management LTD. acquired a new position in Protara Therapeutics in the 4th quarter valued at approximately $3,464,000. Finally, Quadrature Capital Ltd lifted its position in shares of Protara Therapeutics by 39.4% in the 4th quarter. Quadrature Capital Ltd now owns 24,184 shares of the company’s stock worth $129,000 after acquiring an additional 6,838 shares during the period. Institutional investors and hedge funds own 38.13% of the company’s stock.

Protara Therapeutics Company Profile

(Get Free Report)

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.